

Announcement on Changes of the Board of Directors, Audit & Supervisory Board Members and Corporate Officers

Osaka, Japan, April 5, 2024 - Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino) announced that it has decided changes of the Board of Directors, Audit & Supervisory Board Members and Corporate Officers at the meeting of the Board of Directors held today.

The appointments for candidates of the Board of Directors and Audit & Supervisory Board Members will be resolved at the 76th Annual Shareholders Meeting scheduled for June 2024. The changes and appointments of the Board of Directors and Corporate Officers will be officially decided at the meeting of the Board of Directors to be held on the same day after the Annual Shareholders Meeting.

1. Changes of the position of the Board of Directors (scheduled for June 2024):
Except for the following Board of Director, incumbent of the Board of Directors will be re-appointed.
 - Resigning Board of Director:
Kiyooki Idemitsu Executive Officer / Chief Officer, Clinical Development

2. Changes of Audit & Supervisory Board Members (scheduled for June 2024):
Except for the following candidates of Audit & Supervisory Board Members, the incumbent Members will be in term.
 - New candidate of Audit & Supervisory Board Member
Kiyooki Idemitsu
 - Resigning Audit & Supervisory Board Member
Katsuyoshi Nishimura
*: After resigning, he will be appointed as a part-time adviser.
Yasuo Hishiyama (outside) will be re-appointed.

3. Changes of Corporate Officers (scheduled for June 2024):
Except for the following candidates of Corporate Officers, incumbent Corporate Officers will be re-appointed.
 - New candidate of Corporate Officers
 - Hirokazu Kitada Senior Director, Osaka Branch Sales Division
 - Yasushi Hirota Executive Director, Corporate Regulatory Compliance, Safety and Quality Assurance
 - Seishi Katsumata Executive Director, Discovery & Research, Research Project Management Division
 - Kunihiko Ito President, Ono Pharma USA, Inc.

< Reference >

The followings are the appointments of the Board of Directors, Audit & Supervisory Board Members as well as Corporate Officers (scheduled for June 2024).

*: Candidates of the Board of Directors, and Audit & Supervisory Board Members for subject to approval at the 76th Annual Shareholders Meeting

The Board of Directors:

- Gyo Sagara* Representative Director, Chairman of the Board and Chief Executive Officer
- Toichi Takino* Representative Director, President and Chief Operating Officer
- Toshihiro Tsujinaka* Representative Director, Executive Vice President / Executive Director, Corporate Strategy & Planning, Business Design, Sustainability Promotion
- Masao Nomura* Outside Director
- Akiko Okuno* Outside Director
- Shusaku Nagae* Outside Director

Audit & Supervisory Board Members:

- Hironobu Tanisaka Audit & Supervisory Board Member (full-time)
- Kiyooki Idemitsu* Audit & Supervisory Board Member (full-time)
- Yasuo Hishiyama* Outside Audit & Supervisory Board Member
- Akiko Tanabe Outside Audit & Supervisory Board Member

Corporate Officers:

- Akira Takada Corporate Executive Officer / Executive Director, CMC & Production
- Satoshi Takahagi Corporate Executive Officer / Executive Director, Sales and Marketing, Primary Care Business Division
- Hiromu Habashita Corporate Officer / Deputy Executive Director, Discovery & Research
- Shinji Takai Corporate Officer / Head of Medical Affairs
- Masaki Ito Corporate Officer / Division Director, Corporate Strategy & Planning, Business Management Division, Business Management Department, Finance & Accounting / President, Ono Digital health Investment, GK.
- Tatsuya Okamaoto Corporate Officer / Executive Director, Clinical Development, Oncology Clinical Development Division, Global Project Management
- Masayuki Tanigawa Corporate Officer, Executive Director, Corporate Development & Strategy
- Takehiro Yamada Corporate Officer / Senior Director, Risk & Compliance Management Department
- Hirokazu Kitada Corporate Officer / Senior Director, Osaka Branch Sales Division
- Yasushi Hirota Corporate Officer / Executive Director, Corporate Regulatory Compliance, Safety and Quality Assurance
- Seishi Katsumata Corporate Officer / Executive Director, Discovery & Research, Research Project Management Division

- Kunihiko Ito

Corporate Officer / President, Ono Pharma USA, Inc.

Ono Pharmaceutical Co., Ltd.
Corporate Communications
public_relations@ono-pharma.com